Bioventus BVS Tax receivable agreement, percent

Other financials

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept bvs:TaxReceivableAgreementPercent.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →